Publication | Closed Access

Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus

ThrombopoiesisThrombosisCell TherapyVenous ThrombosisCardiovascular DiseaseAtherosclerosisGvhd ProphylaxisStem Cell TransplantationImmunologyHematologyVascular BiologyImmunotherapyMedicineCell TransplantationRisk FactorsThrombotic MicroangiopathyHealth Sciences